Guanfacine

Selective α2A-adrenergic agonist (Shire/Takeda's Intuniv ER) — A-tier evidence as ADHD adjunct in kids/adolescents, B-tier mechanistic story for PFC executive function via Arnsten's HCN-channel-closure model on dendritic spines. Sedating, hypotensive, slows HR — directionally wrong for a 20-year-old whose stack goal is sustained alertness. Cognitive enhancement evidence in healthy adults is mixed-to-null. SKIP for Dylan; revisit only if formal ADHD diagnosis + stimulant Rx ever creates a need for an evening-side adjunct.

Guanfacine is the α2A-selective adrenergic agonist that emerged from the antihypertensive literature (originally approved as Tenex for hypertension in 1986) and was repositioned as Intuniv ER for ADHD in 2009 based on Amy Arnsten's Yale lab work on prefrontal cortex (PFC) catecholamine signaling. Shire developed and licensed Intuniv ER; Takeda acquired Shire in 2019 and is the current marketing-authorization holder.

The α2A-vs-α2B-vs-α2C-vs-clonidine story (this is the key mechanistic distinction):

There are three α2-adrenergic receptor subtypes — α2A, α2B, α2C — distributed differently across the body:

• α2A: Predominant in the locus coeruleus, prefrontal cortex pyramidal cells, and brainstem cardiovascular nuclei. Postsynaptic α2A on PFC pyramidal-cell dendritic spines is the target Arnsten cares about for cognition.
• α2B: Predominantly peripheral vascular smooth muscle. Activation drives initial vasoconstriction (the transient pressor effect seen with high-dose IV α2 agonists).
• α2C: Mostly CNS, modulates dopamine and emotional processing. Activation contributes to sedation.

Clonidine binds all three subtypes roughly equally (in fact, slightly higher affinity for α2A than the others, but only ~3-5×). Guanfacine has ~15-20× higher affinity for α2A than for α2B or α2C. This selectivity is the load-bearing fact for guanfacine being less sedating than clonidine and being preferred for the PFC-executive-function indication.

Two mechanisms operate simultaneously:

1. Presynaptic α2A autoreceptors on noradrenergic neurons (locus coeruleus, peripheral sympathetic ganglia). Activation provides negative feedback — reduces NE release into the synapse. This is the classical antihypertensive mechanism: less sympathetic outflow → lower BP, slower HR. Clonidine is more potent here (10× more potent than guanfacine at presynaptic α2 sites).

2. Postsynaptic α2A on PFC pyramidal-cell dendritic spines (Arnsten's mechanism). This is where guanfacine wins on cognition. Per Arnsten's translational primate work (1980s-2020s):

   • PFC pyramidal cells maintain "Delay-period firing" during working memory tasks via recurrent network connectivity on dendritic spines.
   • Stress/sympathetic load floods PFC with NE → engages α1 + β1 receptors → activates cAMP-PKA pathway → opens HCN channels on dendritic spines → shunts excitatory inputs → working-memory representations collapse. This is the "PFC takes itself offline under stress" model.
   • Postsynaptic α2A activation by guanfacine inhibits cAMP production, closes HCN channels, and strengthens functional connectivity of PFC microcircuits — protects working-memory firing under stress.
   • In monkeys, this produces robust improvements in spatial working memory and behavioral inhibition that are dissociable from sedation (the sedation is a brainstem α2A effect; the cognition is a PFC α2A effect; you can get the cognition without the sedation if you dose right and have the right population).

3. Increased regional cerebral blood flow in dorsolateral PFC (Arnsten group, Neuropsychopharmacology 1998-2000s) — confirmed in non-human primate fMRI/PET work.

Pharmacokinetics (Intuniv ER):

• Tmax: 5 hr (extended-release); IR Tenex Tmax ~3 hr.
• Half-life: ~17 hr (long; supports once-daily dosing).
• Bioavailability: ~80% oral (high; minimal first-pass).
• Metabolism: CYP3A4 primarily; substrate of CYP3A4. Strong CYP3A4 inhibitors (ketoconazole) raise exposure 2-3×; strong inducers (rifampin) cut exposure ~70%.
• Excretion: Renal (~50% unchanged) + hepatic.
• Onset of subjective effect: Sedation can be felt within 1-2 hr; full clinical effect on ADHD symptoms takes 1-2 weeks of titration.

The 20-year-old Dylan-context interpretation: Arnsten's mechanism is real and the primate data is among the cleanest cognitive-pharmacology work in existence. But guanfacine's clinical window of benefit is narrow: it works best in subjects with PFC dysfunction at baseline (ADHD, TBI, age-related decline, stress-loaded patients). In healthy young adults with strong PFC function at baseline, the literature shows ceiling effects — neurons with strong Delay firing under basal conditions show less effect of guanfacine. This is the mechanistic explanation for why the healthy-volunteer trials are inconsistent.